Modified anti-TNF alpha antibody
US7524502B2 · kind B2 · utility
12Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 11, 2002 |
| Grant date | Apr 28, 2009 |
| Priority date | — |
| Expiry date | Oct 30, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.